Key result
In a 33-year-old male, intensification of immunosuppressive therapy for recurrent giant cell myocarditis after heart transplant achieved clinical stability despite severe infections.
Why the study?
Giant cell myocarditis frequently progresses to heart transplantation, but the prognosis and optimal management of recurrent disease post-transplant remain poorly understood.
Population
One 33-year-old male with recurrent GCM following OHT
Design
Case report
Authors
Loading...
Recurrent post-transplant giant cell myocarditis warrants infection vigilance with intensified therapy; leaves optimal regimen open for prospective study.
Case Report (n=1)
Recurrent giant cell myocarditis after heart transplant can be managed with intensified immunosuppression, though this carries a high risk of severe infectious complications.
Frankel et al. (2022) conducted a case report in Recurrent giant cell myocarditis (n=1). Intensification of immunosuppressive regimen was evaluated on Clinical stability and infectious sequelae. In a 33-year-old male, intensification of immunosuppressive therapy for recurrent giant cell myocarditis after heart transplant achieved clinical stability despite severe infections.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: